Replies to post #93658 on Biotech Values

[mcbio]

Re: ACHN

From the presentation slides it appears that the lower dose (500 mg)produces better viral reduction than the 600 mg. Does this make sense? Do you also happen to have an idea of how the additional dosing cohorts would be different?

To his credit I think, the president said something to the effect before that the difference in viral load drop between the 500mg BID dose and the 600mg BID dose is just noise. He indicated before that the viral load reduction between the two doses is effectively the same. The difference in the two ongoing cohorts from the prior ones is that one of the cohorts is a lower dose BID cohort (presumably 400 mg BID or lower) and the other is a higher dose QD cohort (greater than 1000mg QD I assume).

As a comparison, from what I can find, Telapravir monotherapy produced a 5 log reduction but at 14 days of dosing, in a p1 trial.

Yes, Dew and I looked before, but were not able to find an apples-to-apples comparison where we could compare ACH-1625 to telaprevir at 5 days of dosing. The president did make the statement that ACH-1625 produced the greatest log drop at 5 days among HCV compounds so hopefully there is some data out there that supports his assertions.